This study included childhood T-cell acute lymphoblastic leukemia (T-ALL) specimens collected at the time of initial diagnosis, prior to initiation of therapy, from patients enrolled on clinical trials Dana-Farber Cancer Institute Study 05-001 (https://clinicaltrials.gov/ct2/show/NCT00400946), and Children's Oncology Group Study AALL0434 (https://clinicaltrials.gov/ct2/show/NCT00408005). Criteria for data inclusion included availability of adequate tumor material for analysis, and appropriate informed consent and institutional review board (IRB) approval of the respective institutions, in accordance with the Declaration of Helsinki.
"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001513"],"study_history":["The goal of this study is to improve our understanding of the molecular genetics of T-cell acute lymphoblastic leukemia, including the molecular factors that govern treatment response and resistance. Genomic DNA was analyzed by targeted exon sequencing for protein-coding exons of the genes listed below. RNA sequencing analysis was also performed on a subset of samples.
"],"attribution":["Funding Source - Grant NIH/NCI R01 CA193651 - Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115","Principal Investigator - Alejandro Gutierrez, MD - Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115","Co-Investigator - Melissa Burns, MD - Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115"],"repository":["dbGaP"],"description_synonyms":["Forms, acute T cell lymphoblastic leukemia, T-cell leukemia, Antemortem Diagnosis, RNA Sequence Determination, Lymphocytic Leukemia, determination, Effects, chemotherapy, precursor T-cell acute lymphoblastic leukemia/lymphoma, Sequence Determination, Neoplasms, RNA Sequence, lymphoblastic, Benign Neoplasm, Goal, Mini Exon, pharmacotherapy, acute T-cell lymphocytic leukemia, Pharmacotherapies, D4H1S1733E, Tumor, Diagnosis, Malignant, 1-diethyl-2-oxohydrazine, Long Term, Chemotherapies, Precursor T Cell Lymphoblastic Lymphoma, T-Cell Leukemias, Publication., precursor T-lymphoblastic lymphoma/leukemia, T-Cell Acute Lymphocytic Leukemia, Acute T-Cell Leukemia, resistance, Mini-Exon, T-Lymphocytic Leukemia, T Acute Lymphoblastic Leukemia, Mass, symptoms, Dana, Screening, 1, Precursor T-Cell Lymphoblastic Leukemia, Analysis, Antemortem, acute T-cell lymphoblastic leukemia, Precursor T Cell Lymphoblastic Leukemia, Effect, Drug Therapies, T-ALL, T-Lymphocytic Leukemias, Lymphocytic, treatment, study, DAND1, T-cell acute lymphocytic leukemia, Leukemia, precursor T-lymphoblastic leukemia (T-cell ALL), Malignancy, Analyses, T-cell ALL, Longterm, Determination, N, Precursor T-Cell Lymphoblastic Lymphoma, Diethylnitrosamine, Long-Term, Diagnoses and Examinations, Sequence Determinations, Sequencing, Neoplasias, set, Acute T-Lymphocytic, RNA Sequence Analyses, grupos, malignant neoplasm, acute T-cell leukemia, T-cell lymphoblastic leukemia/lymphoma, disease management, Therapies, DAN, RNA Sequencing, Long-Term Effect, Malignancies, Acute T-Cell, precursor T-cell acute lymphoblastic leukemia, Long-Term Effects, HHT1, Diagnose, Cancer, Tumors, Sequence Analyses, Therapy, Antemortem Diagnoses, screening, RNA, findings, grupo, Malignant Neoplasm, Edg, Acute T-Cell Leukemias, N-diethylnitrosamine, RNA Sequence Determinations, T-cell acute lymphoblastic leukemia, Longterm Effect, NO3, T acute lymphoblastic leukemia, T-cell type acute leukemia, Leukemias, Examination and Diagnoses, results, T-Cell Leukemia, Diagnoses, group, Determinations, Postmortem, Screenings, MT, Benign, T-Cell, Mass Screenings, diethylnitrosoamine, Examinations and Diagnoses, Long Term Effects, chemical analysis, Neoplasm, Chemotherapy, acute T cell leukaemia, acute T cell leukemia, Postmortem Diagnosis, N-diethylnitrosoamine, precursor T-lymphoblastic leukemia, END, acute T cell lymphocytic leukemia, Acute T Cell, Lymphoblastic Leukemia, T-cell acute lymphocytic leukaemia, Diagnoses and Examination, Postmortem Diagnoses, primary cancer, T Cell Leukemia, Acute T-Lymphocytic Leukemias, Pharmacotherapy, ensemble, exonic region, Mini-Exons, Lymphoblastic, Rest, signs, Exon, Benign Neoplasms, precursor T-cell acute lymphocytic leukemia/lymphoma, Cancers, Acute T-Lymphocytic Leukemia, Children, Treatments, malignant tumor, T Lymphocytic Leukemia, Longterm Effects, Malignant Neoplasms, Drug, precursor T-cell acute lymphocytic leukemia, Acute, Therapeutic, Precursor T Cell Lymphoblastic Leukemia Lymphoma, DEN, RNA Sequence Analysis, DANA, Treatment, pharmacologic therapy, Precursor T Lymphoblastic Leukemia, T Cell, assay, NDEA, ORW1, groupe, Neoplasia, Gruppe"],"additional_accession":[]},"is_claimable":false,"name":"Mechanisms of Chemotherapy Resistance in T-ALL","description":"The goals of this study are to unravel the molecular mechanisms underlying leukemic transformation and chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL). Towards this end, a cohort of T-ALL lymphoblast specimens was collected at the time of initial T-ALL diagnosis (prior to the start of therapy) from children enrolled on contemporary clinical trials, Children's Oncology Group study AALL0434 and Dana-Farber Cancer Institute 05-001. Samples were analyzed using targeted exon sequencing and RNA sequencing analysis. Results of these analyses form the basis of studies that have been submitted for publication, and will be linked to this entry once published.
","dates":{"last_modification":"2018-01-11","creation":"2017-12-18"},"accession":"phs001513","cross_references":{"MESH":["Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"]}}